On April 30, ZBD released the "2020 Annual Report", the company's revenue and net profit increased -- the operating income reached 3.404 billion yuan, a year-on-year growth of 3.4%; Net profit attributable to shareholders of the listed company was 436 million yuan, up 6.7% year on year.
ZBD main business includes traditional Chinese medicine, chemical medicine, biological medicine and so on. During the reporting period, the trade of traditional Chinese medicine preparations and medicinal materials was the main source of revenue. According to the annual report, the company's revenue from traditional Chinese medicine preparations reached 1.98 billion yuan, up 19.14% year on year; The revenue of Chinese medicinal materials trade reached 791 million yuan, up 31.81% year on year.
In terms of products, the influence of medical insurance policies for Xuesaitong and Shuxuening injection for its core products has been smoothly transited, and the marketing recovery period has entered in 2020. Specifically, the sales volume of Xuesaitong for injection reached 71,195,400 in 2020, with a year-on-year growth of 7.35%; The sales volume of Shuxuening injection reached 29.6484 million, up 3.46% year on year. However, due to the elimination of osteopeptide for injection from the national medical insurance catalog, the sales volume was only 7.2481 million, down 52.71% year-on-year.
It is reported that Xuesaitong for injection and Shuxuening injection are both patent protection products. In 2016, Shuxuening injection won the national patent gold award, and Xuesaitong for injection won the national patent excellence award.
On the same day, ZBD released its first-quarter report of 2021, showing that the company's performance continued to grow steadily this year. From January to March 2021, the operating revenue reached 727 million yuan, up 16.89% year on year, and the net profit attributable to shareholders of the listed company was 155 million yuan, up 22.68% year on year.